Lichtor et al: Approaches to the treatment of brain tumor using cytokine-secreting allogeneic fibroblasts Table 3
a
C57BL/6 mice received a single i.c. injection of a mixture of 103 melanoma cells together with one of the modified fibroblast cell-types (106 cells). Two weeks afterward, mononuclear cells from the spleens of the injected mice (Ficoll-Hypaque) were used for the 51 Cr-release assay. All values represent the mean Âą SD of triplicate determinations. b Toward 51Cr-labeled B16F1 cells; E: T ratio = 100 : 1. c P < 0.005 relative to 51Cr-release for spleen cells from mice injected i.c. with B16F1 cells alone.
Table 4
a
C57BL/6 mice received a single i.c. injection of (103) B16F1 melanoma cells and a s.c. injection of one of the modified fibroblast cell-types (107 cells). Two weeks afterward, mononuclear cells from the spleens of the injected mice (Ficoll-Hypaque) were used for the 51 Cr-release assays. All values represent the mean Âą SD of triplicate determinations. b
E : T ratio = 100 : 1. P < 0.005 relative to 51Cr-release from B16F1 cells co-incubated with spleen cells from mice injected i.c. with B16F1 cells alone. d P < 0.0005 relative to 51Cr-release from B16F1 cells co-incubated with spleen cells from mice injected i.c. with B16F1 cells alone, and P < 0.005 versus 51Cr-release from B16F1 cells co-incubated with spleen cells from mice injected i.c. with RLBA-IL-2 cells. c
116